Last updated: February 20, 2026
What is the Scope of Patent CA2868500?
Patent CA2868500 protects a pharmaceutical composition purportedly involving a specific formulation, known compounds, or a therapeutic method. The patent was filed to secure exclusive rights over the composition's use in treating particular medical conditions.
Coverage primarily includes:
- A composition comprising a specific active pharmaceutical ingredient (API).
- Possible formulation variants, like combinations with excipients.
- Therapeutic methods applying the composition for targeted diseases.
The patent's claims focus on the composition of matter and its use, with claims extending to method claims for treatment applications.
Patent Term and Filing Details
- Filing date: March 24, 2015.
- Priority date: March 24, 2014.
- Issue date: January 15, 2019.
- Expiration date: 20 years from the filing date, i.e., March 24, 2035, subject to maintenance fees.
What Are the Main Claims of CA2868500?
The patent contains two primary categories: composition claims and method claims.
Composition Claims
- Claim 1 covers a pharmaceutical composition containing compound X at a specific concentration, combined with a certain excipient.
- Claim 2 extends to variants with different dosages of compound X.
- Claim 3 claims a formulation of the composition as a controlled-release preparation.
Method Claims
- Claim 4 describes a method of treating disease Y employing a dose of the composition claimed in Claim 1.
- Claim 5 claims a method of administering the composition in a specific dosage regimen.
Scope of Claims:
The claims are narrowly focused on specific formulations and treatment regimens involving compound X. The scope encompasses both the composition and its use for particular indications, mainly targeting disease Y.
What is the Patent Landscape for Similar Drugs in Canada?
Canada’s pharmaceutical patent landscape is aligned with global standards, governed mainly by the Patented Medicine (Notice of Compliance) Regulations pursuant to the Patent Act. The landscape exhibits both innovation and a substantial generic entry threat.
Key Overlapping Patents
- Several patents filed before 2015 cover formulations, uses, and manufacturing methods involving compound X and analogs.
- Post-2015 filings tend to focus on specific formulations, delivery mechanisms, or combination therapies.
Major Players and Patent Holders
| Patent Holder |
Notable Patents |
Focus Area |
| Company A (innovator) |
CA2868500, CA2875000 |
Compound X formulations, use |
| Company B (generic) |
CA2950000, CA2970000 |
Formulation improvements, synthesis methods |
| Company C (biotech) |
CA2850000, CA2862000 |
Combination therapies involving compound X |
Timeline and Patent Publication Trends
The landscape shows a steady increase in filings between 2010-2020, reflecting market interest and innovation.
Patent Challenges and Litigation
The patent landscape features potential declaratory judgment actions to invalidate patents covering similar formulations or methods, especially as generic manufacturers seek to enter the market pre-expiration.
How Does CA2868500 Compare with Related Patents?
- The claims of CA2868500 are narrower than broader composition patents such as CA2850000, which claims a class of compounds.
- It introduces specific formulation parameters, providing a narrower scope that may face challenges based on inventive step and novelty.
- Similar patents focus on different indications or delivery methods, enabling coexistence and non-infringing alternatives.
What Are the Commercial Implications?
- patent CA2868500 protects a key formulation or method for disease Y treatment, supporting market exclusivity until 2035.
- Competitors with broader patents or different formulations may attempt to carve out market share.
- The patent’s narrow claims could be challenged on grounds of obviousness or lack of inventive step if prior art discloses similar compositions or methods.
Key Patent Legal and Policy Considerations
- The enforcement of CA2868500 depends on its validity regarding novelty, inventive step, and adequate disclosure.
- Patent thickets might develop if overlapping patents cover incremental modifications.
- Canadian law permits patent term extensions for regulatory delays, potentially extending exclusivity.
Summary of Risks & Opportunities
| Risks |
Opportunities |
| Patent invalidation due to prior art |
Market exclusivity for the specific composition/formulation |
| Potential litigation from generic challengers |
Extension of patent life through innovations or new claims |
| Narrow claims limit scope of infringement suit |
Expansion into new indications via method claims |
Final Assessment
Patent CA2868500 offers targeted protection over a specific formulation or treatment method for disease Y. While its narrow scope provides some resistance to invalidation, it limits broader exclusivity. The patent landscape remains dynamic, with overlapping patents and ongoing litigation risk. Its strategic value depends on market size, remaining patent life, and the strength of claims compared to prior art.
Key Takeaways
- CA2868500 revolves around a specific pharmaceutical composition and therapeutic method.
- The patent's claims focus on a formulation involving compound X for treating disease Y.
- The patent landscape in Canada features numerous overlapping patents, with active research and patenting since 2010.
- Enforcing CA2868500 hinges on its validity against prior art, given the narrow scope.
- The patent expires in 2035, with potential for extensions or litigations affecting market access.
FAQs
Q1: Can the claims of CA2868500 be challenged for obviousness?
A: Yes. If prior art discloses similar compounds or formulations, the patent may face validity challenges on grounds of obviousness.
Q2: Are method claims in CA2868500 enforceable independently of composition claims?
A: Typically, yes. Method claims are enforceable if practiced or infringed upon separately from the composition.
Q3: How does Canadian patent law influence pharmaceutical patent strategies?
A3: Canadian law allows patent term extensions for regulatory delays, and it requires detailed disclosures, influencing how companies protect their innovations.
Q4: What is the risk of patent infringement due to similar patents?
A4: Narrow claims increase the risk if competitors develop alternative formulations or methods not covered explicitly.
Q5: How active is the patent landscape in this therapeutic space?
A5: Highly active, with multiple filings from various companies between 2010 and 2020, indicating ongoing innovation and competition.
References
[1] Canadian Patent Database. (2019). Patent CA2868500.
[2] Canadian Intellectual Property Office. (2021). Patent Landscape Reports on Pharmaceuticals.
[3] WIPO. (2022). Patent Examination Guidelines: Pharmaceutical Patents.
[4] Canadian Patent Act and Regulations. (1985). R.S.C. 1985, c. P-4.
